Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring

Autor: Julio Pascual, Sergi Pascual, Higini Cao, E. Padilla, María José Pérez-Sáez, Montserrat Folgueiras, Antoni Barrilado-Jackson, Laura Ribera, Dolores Redondo-Pachón, Marta Crespo, Jorge Eguía, Eulàlia Solà-Porta, S Hurtado, Anna Faura, Laura Río-No, Daniel Echeverria-Esnal, Francesc Barbosa

Publikováno v: American Journal of Transplantation

Studies are urgently needed to characterize immunogenicity, efficacy, and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines in kidney transplant (KT) recipients, excluded from major clinical trials. Complex ELISPOT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::490e08a651a9941497956603eb94f6c0
https://doi.org/10.1111/ajt.16854

Scandiatransplant acceptable mismatch program-10 years with an effective strategy for transplanting highly sensitized patients

Autor: Ilse Weinreich, Mats Bengtsson, Jouni Lauronen, Christian Naper, Kaie Lokk, Ilkka Helanterä, Margrét Birna Andrésdóttir, Søren Schwartz Sørensen, Lars Wennberg, Anna Varberg Reisæter, Bjarne Møller, Pernille Koefoed-Nielsen

Publikováno v: Weinreich, I, Bengtsson, M, Lauronen, J, Naper, C, Lokk, K, Helanterä, I, Andrésdóttir, M B, Sørensen, S S, Wennberg, L, Reisaeter, A V, Møller, B & Koefoed-Nielsen, P 2022, ' Scandiatransplant acceptable mismatch program-10 years with an effective strategy for transplanting highly sensitized patients ', American Journal of Transplantation, vol. 22, no. 12, pp. 2869-2879 . https://doi.org/10.1111/ajt.17182
Weinreich, I, Bengtsson, M, Lauronen, J, Naper, C, Lokk, K, Helanterä, I, Andrésdóttir, M B, Sørensen, S S, Wennberg, L, Reisæter, A V, Møller, B & Koefoed-Nielsen, P 2022, ' Scandiatransplant acceptable mismatch program—10 years with an effective strategy for transplanting highly sensitized patients ', American Journal of Transplantation, vol. 22, no. 12, pp. 2869-2879 . https://doi.org/10.1111/ajt.17182

In March 2009, the Scandiatransplant acceptable mismatch program (STAMP) was introduced as a strategy toward improving kidney allocation to highly sensitized patients. Patients with a transplantability score ≤ 2% are potential candidates for the pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8bae2e2efc070136ecc3dba03d10494
http://hdl.handle.net/10138/354246

Timing of Kidney Clamping and Deceased Donor Kidney Transplant Outcomes

Autor: Simon, Ville, Marine, Lorent, Clarisse, Kerleau, Anders, Asberg, Christophe, Legendre, Emmanuel, Morelon, Fanny, Buron, Valérie, Garrigue, Moglie, Le Quintrec, Sophie, Girerd, Marc, Ladrière, Laetitia, Albano, Antoine, Sicard, Denis, Glotz, Carmen, Lefaucheur, Julien, Branchereau, David, Jacobi, Magali, Giral, Etienne, Sicard

Publikováno v: Clin J Am Soc Nephrol
Clinical Journal of the American Society of Nephrology
Clinical Journal of the American Society of Nephrology, 2021, 16 (11), pp.1704-1714. ⟨10.2215/CJN.03290321⟩

International audience; Background and objectives The fact that metabolism and immune function are regulated by an endogenous molecular clock that generates circadian rhythms suggests that the magnitude of ischemia reperfusion, and subsequent inflamm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45d0492d2778e752d2c28a4de5c0e13a
https://doi.org/10.2215/cjn.03290321

Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single-center, open-label TRITON study

Autor: Jesper Kers, Sebastiaan Heidt, Marlies E.J. Reinders, Paula Meij, Dirk Jan A.R. Moes, Helene Roelofs, Aiko P. J. de Vries, Ton J. Rabelink, Cees van Kooten, Koen E. Groeneweg, Johan W. de Fijter, Jonna R. Bank, Dave L. Roelen, Willem E. Fibbe, Frans H.J. Claas, Geertje J Dreyer, Sanne H. Hendriks, Volkert A L Huurman, Melissa van Pel

Publikováno v: American Journal of Transplantation
American journal of transplantation, 21(9), 3055-3065. Wiley-Blackwell
American Journal of Transplantation, 21(9), 3055-3065. WILEY

After renal transplantation, there is a need for immunosuppressive regimens which effectively prevent allograft rejection, while preserving renal function and minimizing side effects. From this perspective, mesenchymal stromal cell (MSC) therapy is o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2b2bfadf72ad4b3db9db1077711c484
https://doi.org/10.1111/ajt.16528